Immunocore's Q2 Earnings Miss Estimates, Kimmtrak Aids Y/Y Revenues
Immunocore Holdings (IMCR) reported Q2 2026 EPS of a loss of $0.02, wider than the Zacks Consensus loss of $0.01. Revenue rose 18.3% Y/Y to $115.9 million, beating the $114 million estimate, driven by Kimmtrak net product sales. Management cited about $6 million of US distributor inventory stocking as a Q3 headwind.
How this was made
The 30-second read
Why it matters
The key trading inputs are the Q2 EPS miss, the revenue beat, and management’s explicit disclosure that distributor inventory stocking will create a Q3 headwind, while underlying sequential growth remains positive excluding that effect.
Market read
Traders can reassess near-term revenue trajectory for Kimmtrak based on the disclosed Q3 inventory normalization headwind, while also monitoring pipeline milestones into late 2026.
What to watch
Investors may underweight the cash balance ($880.2M) and the near-term catalyst risk around Phase III top-line timing (end of 2026) versus the near-term inventory noise.
Background
Immunocore’s marketed product is Kimmtrak (tebentafusp-tebn), with multiple ongoing registrational and Phase III studies in melanoma and related oncology indications.
Ticker impact
Immunocore reported Q2 2026 EPS of -$0.02 vs -$0.01 consensus and Q2 revenue of $115.9M, plus a $6M distributor stocking headwind for Q3.
Likely choppy near-term trading, with downside risk if investors extrapolate the stocking headwind into underlying demand.
The article provides concrete Q2 results and a specific Q3 timing factor ($6M stocking) that can affect sequential revenue expectations, while also noting underlying sequential growth excluding stocking.
Market effects
Biotech sentiment may hinge on continued commercial traction for oncology TCR therapies, with investors watching inventory normalization and Phase III progress.
US and Europe sales growth were both cited as strong, supporting regional demand confidence despite the Q3 stocking effect.
Kimmtrak’s expansion to 30+ countries and ongoing Phase III enrollment keep global adoption and pipeline optionality in focus.
Counterpoint
The EPS miss may be less important than the revenue beat and the statement that underlying sequential growth was 3% excluding the $6M stocking effect.
Key entities
- companyImmunocore Holdings plc
Reported Q2 2026 results and discussed Kimmtrak sales drivers and a Q3 distributor inventory stocking headwind.
- productKimmtrak (tebentafusp-tebn)
Sole marketed drug driving Q2 revenue growth; sales split includes US, Europe, and international regions.
- clinical_trialTEBE-AM study
Phase III registrational study evaluating Kimmtrak monotherapy and with Keytruda; enrollment nearing 540 and top-line data potentially by end of 2026.
